 |
|
New vaccine shows promise for COPD patients at risk for pneumonia
September 08, 2009A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.
Because pneumonia disproportionately affects patients with COPD and frequently causes exacerbations, the Centers for Disease Control currently recommend that all adults with COPD receive the 23-valent pneumococcal polysaccharide vaccination (PPSV23). However, the efficacy of PPSV23 is not well established in the COPD patient population.
"Reasonable effectiveness for this vaccine has been demonstrated in cohort studies in adults with lung disease," said Mark Dransfield, M.D. of the University of Alabama at Birmingham and lead author of the study. "[However,] debate remains about its immunogenicity and effectiveness in COPD."
Dr. Dransfield and colleagues sought to determine the efficacy of a newer type of vaccine, PCV7, a protein conjugate vaccine, which attaches a weak antigen (in this case, the pneumococcal polysaccharide antigen) to a stronger antigen (the diphtheria toxin) in the hope that the stronger antigen with provoke a more forceful defense from the immune system.
"Conjugated vaccines were originally intended for young children who respond poorly to polysaccharide antigens," said Dr. Dransfield. "We wanted to see whether they could have a similar effect in the COPD patient population in whom immune responses may also be blunted."
Results of the randomized open label trial of 120 adults with moderate to severe COPD showed that, while both the PPSV23 vaccine and the PCV7 vaccine were well-tolerated, the PCV7 vaccine produced superior immune responses on several measures of immunogenicity. Among patients randomized to take the PCV7 vaccine, the fraction exhibiting a twofold increase in serotype-specific IgG antibodies was higher in five of the seven serotypes tested. Blood drawn from patients who had received the PCV7 vaccine was also more effective at killing pneumococci in six of seven serotypes tested one month after vaccination.
"We have shown that PCV7 induces a superior immune response to PPSV23 in COPD at one month post-vaccination," concluded Dr. Dransfield. "Both vaccines elicit responses comparable to those previous observed in health elderly patients." Older age and prior vaccination with PPSV23 dampened the efficacy of the PCV7 vaccine, however.
A vaccine in development that contains the capsule of 13 pneumococcal serotypes, called PCV13 (compared to PCV7 which has seven) is hoped to expand the coverage of the vaccine.
"We hope that future research will confirm the superior immunogenicity of PCV13 in COPD," he added. "We also want to determine the relative duration of the immune response following PPSV23 and conjugate vaccination and to identify the immunologic correlates of protection against both invasive and non-invasive pneumococcal disease. We believe our data provide the rationale for further study of the clinical efficacy of protein-conjugate pneumococcal vaccines in the high risk COPD population."
American Thoracic Society
Dr. Dransfield and colleagues sought to determine the efficacy of a newer type of vaccine, PCV7, a protein conjugate vaccine, which attaches a weak antigen (in this case, the pneumococcal polysaccharide antigen) to a stronger antigen (the diphtheria toxin) in the hope that the stronger antigen with provoke a more forceful defense from the immune system.
"Conjugated vaccines were originally intended for young children who respond poorly to polysaccharide antigens," said Dr. Dransfield. "We wanted to see whether they could have a similar effect in the COPD patient population in whom immune responses may also be blunted."
Results of the randomized open label trial of 120 adults with moderate to severe COPD showed that, while both the PPSV23 vaccine and the PCV7 vaccine were well-tolerated, the PCV7 vaccine produced superior immune responses on several measures of immunogenicity. Among patients randomized to take the PCV7 vaccine, the fraction exhibiting a twofold increase in serotype-specific IgG antibodies was higher in five of the seven serotypes tested. Blood drawn from patients who had received the PCV7 vaccine was also more effective at killing pneumococci in six of seven serotypes tested one month after vaccination.
"We have shown that PCV7 induces a superior immune response to PPSV23 in COPD at one month post-vaccination," concluded Dr. Dransfield. "Both vaccines elicit responses comparable to those previous observed in health elderly patients." Older age and prior vaccination with PPSV23 dampened the efficacy of the PCV7 vaccine, however.
A vaccine in development that contains the capsule of 13 pneumococcal serotypes, called PCV13 (compared to PCV7 which has seven) is hoped to expand the coverage of the vaccine.
"We hope that future research will confirm the superior immunogenicity of PCV13 in COPD," he added. "We also want to determine the relative duration of the immune response following PPSV23 and conjugate vaccination and to identify the immunologic correlates of protection against both invasive and non-invasive pneumococcal disease. We believe our data provide the rationale for further study of the clinical efficacy of protein-conjugate pneumococcal vaccines in the high risk COPD population."
American Thoracic Society
Chronic Obstructive Pulmonary Disease Current Events and Chronic Obstructive Pulmonary Disease News RSSSurvey: Awareness of COPD is rising, but understanding is still low
Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
'Superobesity,' chronic disease burden associated with risk of death following bariatric surgery
Veterans classified as superobese and those with a higher chronic disease burden appear more likely to die within a year of having bariatric surgery, according to a report in the October issue of Archives of Surgery, one of the JAMA/Archives journals.
Portable and precise gas sensor could monitor pollution and detect disease
In the air, it is a serious pollutant. In the body, it plays a role in heart rate, blood flow, nerve signals and immune function.
UT scientists discover link between protein and lung disease
In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).
ADA publishes practice guidelines for nutrition care for patients with spinal cord injury
The American Dietetic Association has published new evidence-based nutrition practice guidelines for registered dietitians on nutrition care for patients with spinal cord injury.
LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease
Stephania Cormier, Ph.D., Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, has shown for the first time that early exposure to environmentally persistent free radicals (present in airborne ultrafine particulate matter) affects long-term lung function.
Severe COPD may lead to cognitive impairment
Severe chronic obstructive pulmonary disease (COPD) is associated with lower cognitive function in older adults, according to research from Mount Sinai School of Medicine.
Group Health Cooperative shows investing in more primary care pays for itself
An evaluation of recent innovations in delivering primary care at a Group Health Cooperative medical center shows significant success and rapid return on investment.
Top notch decisions in the developing airways bring insights into lung disease
In the normal lung, the airways are lined by a balanced mixture of ciliated, secretory and neuroendocrine cells which perform functions as diverse as air humidification, detoxification, and clearance of environmental particles.
Investigation finds that cigarette smoking does not affect everyone in same way
Cigarette smoking induced COPD, or chronic obstructive pulmonary disease, is a disease that results in severe breathing difficulty.
More Chronic Obstructive Pulmonary Disease Current Events and Chronic Obstructive Pulmonary Disease News Articles
 |
Chronic Obstructive Pulmonary Disease (Fast Facts) by William Macnee (Author), Stephen I., M.D. Rennard (Author) Chronic obstructive pulmonary disease (COPD) is a heterogeneous collection of respiratory syndromes with overlapping manifestations. As well as the characteristic shortness of breath, the disease is associated with a number of comorbidities that can present major clinical problems for the individual. This fully updated second edition of "Fast Facts: Chronic Obstructive Pulmonary Disease" offers a concise and expert review of: the disease process, its causes and progression; diagnostic techniques, including lung function tests and imaging; differential diagnoses; the main clinical features, systemic effects and comorbidities; current treatments to reduce symptoms and improve lung function in stable disease; the prevention and management of acute exacerbations; the latest clinical trial... |
 |
Chronic Obstructive Pulmonary Disease (COPD) Anatomical Chart Unmounted by lww Defines COPD along with causes, symptoms, diagnosis and treatments. Shows respiratory anatomy and illustrates two disorders associated with COPD: Emphysema and Chronic Bronchitis. |
 |
COPD Awareness Ribbon Mouse Pad by MyHeritageWear.com The COPD Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the COPD Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your COPD Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Chronic Respiratory Disorders (118) CD-ROM by Concept Media, a division of Jobson Medical Information LLC 5 CD series including these programs: [118.1] Chronic Obstructive Pulmonary Disease; [118.2] Cystic Fibrosis; |
 |
FlameEz-Lung, 60 Capsules/Bottle by FlameEz Chronic Obstructive Pulmonary Disease (COPD) is progressive inflammatory disease affecting the respiratory tract and the lungs. Inflammation causes destruction of airways and lung tissues. If inflammation persists, the damage to the airways and lungs may not be reversed. Recent studies also suggest that inflammation is a critical component in lung cancer development, progression and metastasis. Inflammation induces the release of a variety of inflammatory cytokines that cause oxidative damage, DNA mutation, and cell transformation. Inflammation also plays a key role in survival and expansion of tumor cells. Since tumor cells produce various substances that attract inflammatory cells, which are indispensable participants in tissue disruption and metastasis, inflammation has been described... |
|
DVD, COPD Pathophysiology by GlaxoSmithKlie DVD. | |
 |
Life and Breath: Preventing, Treating and Reversing Chronic Obstructive Pulmonary Disease by Neil Schachter (Author) The fourth leading cause of death in the United States, COPD, or chronic obstructive pulmonary disease, affects an estimated 35 million Americans. Yet only half are aware that they are seriously ill. Life and Breath, by Dr. Neil Schachter, is the first book that alerts people to their risks for COPD and explains the steps they need to take to prevent the development of this debilitating and often fatal lung disease. Life and Breath begins witha quick quiz to rate your risk for COPD. It explains the steps of a complete pulmonary work-up and teaches you about the painless, inexpensive six-second test that can save your life. We all know that diet, exercise, and environmental changes can reduce the risk of heart disease and some types of cancer. Now, for the first time, Life... |
 |
Coping with COPD: Understanding, Treating, and Living with Chronic Obstructive Pulmonary Disease by Elaine Fantle Shimberg (Author), Thomas L. Petty M.D. (Foreword) The first hands-on guide to living and coping with an insidious disease that affects tens of millions of people Experts estimate that as many as thirty-five million Americans literally cannot catch their breath-they are suffering from Chronic Obstructive Pulmonary Disease. The fourth-leading cause of death in America, COPD is a combination of chronic bronchitis and emphysema with airflow obstruction. In this clear, concise, and up-to-date guide to dealing with and living well with COPD, readers will learn: - How to navigate activities of daily living, from applying make-up to continuing work - How to quite smoking-at any age - How oxygen therapy may help you - How to tailor diet to meet new nutritional needs - How to foster a useful patient/doctor... |
|
Pathophysiology of Chronic Obstructive Pulmonary Disease [VHS] Starring: Lippincott | |
 |
Acute Exacerbations of Chronic Obstructive Pulmonary Disease (Lung Biology in Health and Disease) by Nikos Siafakas (Editor), Nicholas R. Anthonisen (Editor), Dimitris Georgopoulos (Editor) Aids practitioners who are looking to more effectively diagnose, treat, and manage patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Discusses pulmonary gas exchange, muscle function and breathing, water/electrolyte imbalances, and end stage disease in AECOPD. |
| © 2009 BrightSurf.com |